Bret Hulick was in his second year of medical school at LECOM in Erie, analyzing the case of a 24-year-old colon cancer ...

We look forward to evaluating dostarlimab-gxly in certain colorectal cancers in our ongoing AZUR-1 and AZUR-2 registrational studies." GSK said the patients in the study did not experience adverse ...

The currently recruiting AZUR-2 trial aims to decrease this knowledge gap by investigating how dostarlimab compares with standard perioperative care in MSI-H/dMMR colon cancer. 36 There remains a ...

In what can be termed a never-seen-before medical miracle, a small group of people with colorectal cancer achieved 100% ...

Our colorectal trial, supported by F ... in a Phase 1b/2 trial combining LIXTE's LB-100 with GSK's immunotherapy, dostarlimab-gxly, targeting ovarian clear cell carcinoma. Dosing of the first ...